Ticagrelor · Brilinta, AZD-6140

What is Ticagrelor?

Ticagrelor is an orally bioavailable P2Y12 platelet receptor antagonist that reversibly binds to the ADP receptor on platelets to inhibit platelet activation and aggregation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Brilinta, AZD-6140

Drug type

Small molecule

Targets

P2Y12 receptor (P2RY12)

Mechanism

Antagonist of P2Y12 receptor (P2RY12)

Pathways

platelet activation, platelet aggregation

Therapy area

Cardiovascular

Developer

Astrazeneca

In trials of

COLL

FDA status

Approved as Brilinta (July 20, 2011), NDA022433 · FDA label

UNII

GLH0314RVC

✅ FDA-approved uses

• Acute coronary syndrome or history of myocardial infarction
• Coronary artery disease at high risk for myocardial infarction or stroke
• Acute ischemic stroke or transient ischemic attack

From the indications section of the FDA label (version of Apr 14, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non ST Segment Elevation Acute Coronary SyndromeNon-ST-Segment Elevation Myocardial Infarction (NSTEMI)Unstable AnginaUnstable Angina Pectoris

Other drugs acting on P2RY12

Sources

• FDA label (DailyMed)
• FDA label Brilinta (2026-04-14), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT02612116
• ClinicalTrials.gov NCT02612116
• ClinicalTrials.gov NCT02612116
• ClinicalTrials.gov NCT02939248

Updated Oct 3, 2026.